成人成長ホルモン欠乏症 (AGHD) の世界市場：洞察・疫学・市場予測 (～2034年)

当レポートでは、世界の主要7カ国における成人成長ホルモン欠乏症 (AGHD) の市場を調査し、疾患の背景・概要、疫学、治療と管理の概要、市場促進要因と障壁、アンメットニーズ、上市薬およびパイプライン薬のプロファイル、主要国の市場規模の推移・予測、競合情勢などをまとめ、最良の機会を発掘し、市場の潜在力を評価します。

対象地域

• 米国
• 欧州5カ国（ドイツ・フランス・イタリア・スペイン・英国）
• 日本

調査期間：2020年～2034年

レポートハイライト

• 成人成長ホルモン欠乏症 (AGHD) の市場は、疾患に対する認識の高まりと、医療支出の世界的増加により、今後数年間で変化を示すと考えられています。
• 企業や研究機関は、成人成長ホルモン欠乏症 (AGHD) の研究開発に影響を与える可能性のある課題を分析し、その機会を探るべく取り組んでいます。開発中の治療薬は、病態を治療/改善するための新規アプローチに焦点を当てています。
• 大手企業は成人成長ホルモン欠乏症 (AGHD) の治療薬の開発に取り組んでいます。新たな治療薬の上市は市場に大きな影響を与える見通しです。
• 成人成長ホルモン欠乏症 (AGHD) の新規治療薬の開発には、疾患病態のより深い理解が必要です。
• 当社の開発段階ごと（第III相および第II相）のパイプラインアセットに関する詳細な分析、さまざまな新興動向、詳細な臨床プロファイル、主なクロスコンペティション、発売日、製品開発活動を含むパイプライン薬の比較分析は、研究開発活動の全体的なシナリオを特定することで、治療ポートフォリオに関する意思決定プロセスにおいてクライアントを支援します。

目次

第1章 重要な洞察

第2章 成人成長ホルモン欠乏症 (AGHD) ：エグゼクティブサマリー

第3章 成人成長ホルモン欠乏症 (AGHD) ：競合分析

第4章 成人成長ホルモン欠乏症 (AGHD) ：市場概要

• 総市場のシェア (％) の分布：2020年
• 総市場のシェア (％) の分布：2034年

第5章 成人成長ホルモン欠乏症 (AGHD) ：疾患の背景・概要

• 兆候と症状
• 病態生理
• リスク因子
• 診断

第6章 ペイシェントジャーニー

第7章 成人成長ホルモン欠乏症 (AGHD) ：疫学・患者人口

• 疫学：主要調査結果
• 前提・根拠：主要7カ国
• 疫学シナリオ：主要7カ国
  • 主要7カ国における成人成長ホルモン欠乏症 (AGHD) の疫学シナリオ：2020-2034年
• 疫学：米国
• 疫学：欧州5カ国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 疫学：日本

第8章 治療アルゴリズム・現在の治療薬・医療行為

• 成人成長ホルモン欠乏症 (AGHD) の治療と管理
• 成人成長ホルモン欠乏症 (AGHD) の治療アルゴリズム

第9章 アンメットニーズ

第10章 成人成長ホルモン欠乏症 (AGHD) 治療の主なエンドポイント

第11章 上市製品

• 主要7カ国の上市製品リスト
• 医薬品名・企業名
  • 製品説明
  • 規制のマイルストーン
  • その他の開発活動
  • 重要臨床試験
  • 主要臨床試験の概要

第12章 新興治療薬

• 主なクロスコンペティション
• 医薬品名・企業名
  • 製品説明
  • その他の開発活動
  • 臨床開発
  • 安全性と有効性
  • 製品プロファイル

第13章 成人成長ホルモン欠乏症 (AGHD) ：主要7カ国市場の分析

• 主要調査結果
• 主要7カ国の市場規模
• 主要7カ国の市場規模：治療薬別

第14章 属性分析

第15章 主要7カ国：市場の展望

• 米国：市場規模
• 欧州5カ国：市場規模・展望
• ドイツ
• フランス
• イタリア
• スペイン
• 英国
• 日本市場の展望

第16章 成人成長ホルモン欠乏症 (AGHD) ：アクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightの能力

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Adult Growth Hormone Deficiency (AGHD) Epidemiology (2020-2034)
• Table 2: 7MM Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases (2020-2034)
• Table 3: Adult Growth Hormone Deficiency (AGHD) Epidemiology in the United States (2020-2034)
• Table 4: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Germany (2020-2034)
• Table 6: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Adult Growth Hormone Deficiency (AGHD) Epidemiology in France (2020-2034)
• Table 8: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Italy (2020-2034)
• Table 10: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Spain (2020-2034)
• Table 12: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Adult Growth Hormone Deficiency (AGHD) Epidemiology in the UK (2020-2034)
• Table 14: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Japan (2020-2034)
• Table 16: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Adult Growth Hormone Deficiency (AGHD) Epidemiology (2020-2034)
• Figure 2: 7MM Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Adult Growth Hormone Deficiency (AGHD) Epidemiology in the United States (2020-2034)
• Figure 4: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Germany (2020-2034)
• Figure 6: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Adult Growth Hormone Deficiency (AGHD) Epidemiology in France (2020-2034)
• Figure 8: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Italy (2020-2034)
• Figure 10: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Spain (2020-2034)
• Figure 12: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Adult Growth Hormone Deficiency (AGHD) Epidemiology in the UK (2020-2034)
• Figure 14: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Adult Growth Hormone Deficiency (AGHD) Epidemiology in Japan (2020-2034)
• Figure 16: Adult Growth Hormone Deficiency (AGHD) Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Adult Growth Hormone Deficiency (AGHD) - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Adult Growth Hormone Deficiency (AGHD), historical and forecasted epidemiology as well as the Adult Growth Hormone Deficiency (AGHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Adult Growth Hormone Deficiency (AGHD) market report provides current treatment practices, emerging drugs, Adult Growth Hormone Deficiency (AGHD) market share of the individual therapies, current and forecasted Adult Growth Hormone Deficiency (AGHD) market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Adult Growth Hormone Deficiency (AGHD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Adult Growth Hormone Deficiency (AGHD) Disease Understanding and Treatment Algorithm

The DelveInsight Adult Growth Hormone Deficiency (AGHD) market report gives a thorough understanding of the Adult Growth Hormone Deficiency (AGHD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Adult Growth Hormone Deficiency (AGHD).

Treatment

It covers the details of conventional and current medical therapies available in the Adult Growth Hormone Deficiency (AGHD) market for the treatment of the condition. It also provides Adult Growth Hormone Deficiency (AGHD) treatment algorithms and guidelines in the United States, Europe, and Japan.

Adult Growth Hormone Deficiency (AGHD) Epidemiology

The Adult Growth Hormone Deficiency (AGHD) epidemiology division provide insights about historical and current Adult Growth Hormone Deficiency (AGHD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Adult Growth Hormone Deficiency (AGHD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Adult Growth Hormone Deficiency (AGHD) Epidemiology

The epidemiology segment also provides the Adult Growth Hormone Deficiency (AGHD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Adult Growth Hormone Deficiency (AGHD) Drug Chapters

Drug chapter segment of the Adult Growth Hormone Deficiency (AGHD) report encloses the detailed analysis of Adult Growth Hormone Deficiency (AGHD) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Adult Growth Hormone Deficiency (AGHD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Adult Growth Hormone Deficiency (AGHD) treatment.

Adult Growth Hormone Deficiency (AGHD) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Adult Growth Hormone Deficiency (AGHD) treatment.

Adult Growth Hormone Deficiency (AGHD) Market Outlook

The Adult Growth Hormone Deficiency (AGHD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Adult Growth Hormone Deficiency (AGHD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Adult Growth Hormone Deficiency (AGHD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Adult Growth Hormone Deficiency (AGHD) market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Adult Growth Hormone Deficiency (AGHD) market in 7MM.

The United States Market Outlook

This section provides the total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Adult Growth Hormone Deficiency (AGHD) market size and market size by therapies in Japan is also mentioned.

Adult Growth Hormone Deficiency (AGHD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Adult Growth Hormone Deficiency (AGHD) market or expected to get launched in the market during the study period 2020-2034. The analysis covers Adult Growth Hormone Deficiency (AGHD) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adult Growth Hormone Deficiency (AGHD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adult Growth Hormone Deficiency (AGHD) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Adult Growth Hormone Deficiency (AGHD) emerging therapies.

Reimbursement Scenario in Adult Growth Hormone Deficiency (AGHD)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Adult Growth Hormone Deficiency (AGHD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Adult Growth Hormone Deficiency (AGHD) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Adult Growth Hormone Deficiency (AGHD) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Adult Growth Hormone Deficiency (AGHD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Adult Growth Hormone Deficiency (AGHD) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Adult Growth Hormone Deficiency (AGHD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Adult Growth Hormone Deficiency (AGHD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Adult Growth Hormone Deficiency (AGHD) market

Report Highlights:

• In the coming years, Adult Growth Hormone Deficiency (AGHD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Adult Growth Hormone Deficiency (AGHD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Adult Growth Hormone Deficiency (AGHD). Launch of emerging therapies will significantly impact the Adult Growth Hormone Deficiency (AGHD) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Adult Growth Hormone Deficiency (AGHD)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Adult Growth Hormone Deficiency (AGHD) Report Insights

• Patient Population
• Therapeutic Approaches
• Adult Growth Hormone Deficiency (AGHD) Pipeline Analysis
• Adult Growth Hormone Deficiency (AGHD) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Adult Growth Hormone Deficiency (AGHD) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Adult Growth Hormone Deficiency (AGHD) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Adult Growth Hormone Deficiency (AGHD) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Adult Growth Hormone Deficiency (AGHD) market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Adult Growth Hormone Deficiency (AGHD) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Adult Growth Hormone Deficiency (AGHD) market size during the forecast period (2024-2034)?
• At what CAGR, the Adult Growth Hormone Deficiency (AGHD) market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Adult Growth Hormone Deficiency (AGHD) market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Adult Growth Hormone Deficiency (AGHD) market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Adult Growth Hormone Deficiency (AGHD)?
• What is the historical Adult Growth Hormone Deficiency (AGHD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Adult Growth Hormone Deficiency (AGHD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Adult Growth Hormone Deficiency (AGHD)?
• Out of all 7MM countries, which country would have the highest prevalent population of Adult Growth Hormone Deficiency (AGHD) during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Adult Growth Hormone Deficiency (AGHD) treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Adult Growth Hormone Deficiency (AGHD) in the USA, Europe, and Japan?
• What are the Adult Growth Hormone Deficiency (AGHD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Adult Growth Hormone Deficiency (AGHD)?
• How many therapies are developed by each company for Adult Growth Hormone Deficiency (AGHD) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Adult Growth Hormone Deficiency (AGHD) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Adult Growth Hormone Deficiency (AGHD) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Adult Growth Hormone Deficiency (AGHD) and their status?
• What are the key designations that have been granted for the emerging therapies for Adult Growth Hormone Deficiency (AGHD)?
• What are the global historical and forecasted market of Adult Growth Hormone Deficiency (AGHD)?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Adult Growth Hormone Deficiency (AGHD) market
• To understand the future market competition in the Adult Growth Hormone Deficiency (AGHD) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Adult Growth Hormone Deficiency (AGHD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Adult Growth Hormone Deficiency (AGHD) market
• To understand the future market competition in the Adult Growth Hormone Deficiency (AGHD) market

Table of Contents

1. Key Insights

2. Executive Summary of Adult Growth Hormone Deficiency (AGHD)

3. Competitive Intelligence Analysis for Adult Growth Hormone Deficiency (AGHD)

4. Adult Growth Hormone Deficiency (AGHD): Market Overview at a Glance

• 4.1. Adult Growth Hormone Deficiency (AGHD) Total Market Share (%) Distribution in 2020
• 4.2. Adult Growth Hormone Deficiency (AGHD) Total Market Share (%) Distribution in 2034

5. Adult Growth Hormone Deficiency (AGHD): Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Adult Growth Hormone Deficiency (AGHD) Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Adult Growth Hormone Deficiency (AGHD) Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Adult Growth Hormone Deficiency (AGHD) Treatment and Management
• 8.2. Adult Growth Hormone Deficiency (AGHD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Adult Growth Hormone Deficiency (AGHD) Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Adult Growth Hormone Deficiency (AGHD): Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Adult Growth Hormone Deficiency (AGHD) Market Size in 7MM
• 13.3. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in the United States
  • 15.1.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in Germany
  • 15.3.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in France
  • 15.4.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in Italy
  • 15.5.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in Spain
  • 15.6.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Adult Growth Hormone Deficiency (AGHD) Total Market Size in the United Kingdom
  • 15.7.2. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Adult Growth Hormone Deficiency (AGHD) Total Market Size in Japan
  • 15.8.3. Adult Growth Hormone Deficiency (AGHD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Adult Growth Hormone Deficiency (AGHD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.